Molecular Partners AG
Molecular Partners AG, a pioneering biotechnology company headquartered in Zurich, Switzerland (CH), is at the forefront of developing innovative therapies for serious diseases. Founded in 2004, the company has made significant strides in the field of protein therapeutics, particularly with its proprietary DARPins (Designed Ankyrin Repeat Proteins) technology, which offers unique advantages in specificity and stability. With a strong focus on oncology and infectious diseases, Molecular Partners has established itself as a key player in the biopharmaceutical industry. The company’s lead product candidates, including MP0310 and MP0420, showcase its commitment to addressing unmet medical needs through cutting-edge science. Recognised for its robust pipeline and strategic partnerships, Molecular Partners AG continues to enhance its market position, driving advancements in targeted therapies that promise to transform patient outcomes.
DitchCarbon Score
How does Molecular Partners AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Molecular Partners AG's score of 23 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Molecular Partners AG's reported carbon emissions
Molecular Partners AG, headquartered in Switzerland (CH), currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Molecular Partners AG may still be in the early stages of formalising its climate commitments or reporting practices. As the biopharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Molecular Partners AG to establish clear emissions reduction strategies and commitments to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Molecular Partners AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
